^
Association details:
| Biomarker: | KRAS exon 12 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Prolia (denosumab) (RANK ligand inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
DEnosumab plus PD-1 Inhibitor for MAINtenance Therapy of Advanced KRAS-Mutant NSCLC - A Prospective, Single-Arm, Phase II Study (DEMAIN)
Published date:
08/08/2023
Excerpt:
Pts were treated with PD-1 inhibitor (q3w) and denosumab (120mg, q4w) for subsequent maintenance therapy regardless of bone metastases....Subgroup analysis suggested a greater survival benefit in patients with KRAS codon 12 mutations than in patients with KRAS non-codon 12 mutations (mPFS1, 365 vs 267 days; p=0.002; mPFS2, 224 vs 120 days; p=0.005).
Secondary therapy:
PD-L1 inhibitor
